Catalyst Pharmaceutical Partners(CPRX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

CPRX Catalyst Pharmaceutical Partners

盘前交易 12-16 06:50:19 EST

24.18

+0.56

+2.37%

盘前24.26

+0.08+0.33%

06:25 EST

最高25.14	最低23.69	成交量216.61万
今开23.69	昨收23.62	日振幅6.14%
总市值29.72亿	流通市值27.81亿	总股本1.23亿
成交额5,253万	换手率1.88%	流通股本1.15亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"CPRX","market":"US","secType":"STK","nameCN":"Catalyst Pharmaceutical Partners","latestPrice":24.18,"timestamp":1765832400000,"preClose":23.62,"halted":0,"volume":2166131,"hourTrading":{"tag":"盘前","latestPrice":24.26,"preClose":24.18,"latestTime":"06:25 EST","volume":1,"amount":24.26,"timestamp":1765884343796},"delay":0,"floatShares":115016976,"shares":122912387,"eps":1.7084,"marketStatus":"盘前交易","change":0.56,"latestTime":"12-16 06:50:19 EST","open":23.69,"high":25.14,"low":23.69,"amount":52528928.021196,"amplitude":0.061389,"askPrice":24.29,"askSize":205,"bidPrice":23.81,"bidSize":205,"shortable":3,"etf":0,"ttmEps":1.7084,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1765895400000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":1162962000000,"exchange":"NASDAQ","adjPreClose":24.18,"preHourTrading":{"tag":"盘前","latestPrice":24.26,"preClose":24.18,"latestTime":"06:25 EST","volume":1,"amount":24.26,"timestamp":1765884343796},"postHourTrading":{"tag":"盘后","latestPrice":24.5,"preClose":24.18,"latestTime":"19:55 EST","volume":41374,"amount":1000409.1303,"timestamp":1765846503060},"volumeRatio":1.4474374755702084,"impliedVol":0.5804,"impliedVolPercentile":0.7229},"requestUrl":"/m/hq/s/CPRX","defaultTab":"news","newsList":[{"id":"1141319774","title":"Catalyst Pharmaceutical Partners与Lupin终止专利诉讼","url":"https://stock-news.laohu8.com/highlight/detail?id=1141319774","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1141319774?lang=zh_cn&edition=full","pubTime":"2025-08-27 07:18","pubTimestamp":1756250293,"startTime":"0","endTime":"0","summary":"Catalyst Pharmaceutical Partners与Lupin将终止Catalyst/Serb与Lupin之间的专利诉讼。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IE0034390439.USD","CPRX","IE00B19Z6F94.USD"],"gpt_icon":0},{"id":"1142264537","title":"Catalyst Pharmaceuticals宣布与Lupin Pharmaceuticals就Firdapse®（阿米吡啶）专利诉讼达成和解","url":"https://stock-news.laohu8.com/highlight/detail?id=1142264537","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1142264537?lang=zh_cn&edition=full","pubTime":"2025-08-25 20:05","pubTimestamp":1756123516,"startTime":"0","endTime":"0","summary":"Catalyst Pharmaceuticals宣布与Lupin Pharmaceuticals就Firdapse®（阿米吡啶）专利诉讼达成和解。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CPRX","IE00B19Z6F94.USD","IE0034390439.USD","BK4139"],"gpt_icon":0},{"id":"2557569524","title":"Catalyst Pharmaceuticals, Inc.盘中异动 早盘股价大跌5.66%","url":"https://stock-news.laohu8.com/highlight/detail?id=2557569524","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557569524?lang=zh_cn&edition=full","pubTime":"2025-08-07 21:31","pubTimestamp":1754573516,"startTime":"0","endTime":"0","summary":"北京时间2025年08月07日21时31分，Catalyst Pharmaceuticals, Inc.股票出现异动，股价大幅跳水5.66%。截至发稿，该股报20.56美元/股，成交量10.3748万股，换手率0.09%，振幅3.85%。Catalyst Pharmaceuticals, Inc.股票所在的生物技术行业中，整体跌幅为0.12%。其相关个股中，Palisade Bio, Inc.、Niagen Bioscience, Inc.、Xeris制药涨幅较大，Palisade Bio, Inc.、Processa Pharmaceuticals, Inc.、Bioxcel Therapeutics, Inc.较为活跃，换手率分别为438.34%、62.38%、21.20%，振幅较大的相关个股有Lantern Pharma Inc.、Palisade Bio, Inc.、Xeris制药，振幅分别为101.17%、39.00%、12.75%。Catalyst Pharmaceuticals, Inc.公司简介：Catalyst Pharmaceuticals Inc是一家生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202508072131569739b19d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202508072131569739b19d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","IE0034390439.USD","CPRX","IE00B19Z6F94.USD"],"gpt_icon":0},{"id":"2518273726","title":"Catalyst Pharmaceuticals, Inc.盘中异动 早盘急速下挫5.10%报20.84美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2518273726","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518273726?lang=zh_cn&edition=full","pubTime":"2025-03-10 22:04","pubTimestamp":1741615445,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日22时04分，Catalyst Pharmaceuticals, Inc.股票出现异动，股价大幅跳水5.10%。截至发稿，该股报20.84美元/股，成交量14.9957万股，换手率0.12%，振幅3.57%。Catalyst Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.03%。其相关个股中，Checkpoint Therapeutics, Inc.、Mineralys Therapeutics, Inc.、Trevi Therapeutics, Inc.涨幅较大，Scisparc Ltd.、Dogwood Therapeutics, Inc.、Aeon Biopharma, Inc.较为活跃，换手率分别为675.90%、345.51%、94.18%，振幅较大的相关个股有Dogwood Therapeutics, Inc.、Scisparc Ltd.、Pmgc Holdings Inc.，振幅分别为41.36%、40.24%、32.14%。Catalyst Pharmaceuticals, Inc.公司简介：Catalyst Pharmaceuticals Inc是一家生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031022040598a2a59c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031022040598a2a59c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE0034390439.USD","CPRX","IE00B19Z6F94.USD","BK4139"],"gpt_icon":0},{"id":"2516633545","title":"Baird：维持Catalyst Pharmaceuticals(CPRX.US)评级，由优于大市调整至优于大市评级, 目标价由28.00美元调整至32.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2516633545","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516633545?lang=zh_cn&edition=full","pubTime":"2025-03-03 20:51","pubTimestamp":1741006290,"startTime":"0","endTime":"0","summary":"Baird：维持Catalyst Pharmaceuticals(CPRX.US)评级，由优于大市调整至优于大市评级, 目标价由28.00美元调整至32.00美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/03205148492764.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["CPRX"],"gpt_icon":0},{"id":"2516548200","title":"Catalyst Pharmaceuticals, Inc.2024财年实现净利润1.64亿美元，同比增加129.66%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516548200","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516548200?lang=zh_cn&edition=full","pubTime":"2025-03-03 00:01","pubTimestamp":1740931292,"startTime":"0","endTime":"0","summary":"3月3日，Catalyst Pharmaceuticals, Inc.公布财报，公告显示公司2024财年净利润为1.64亿美元，同比增加129.66%；其中营业收入为4.92亿美元，同比增加23.62%，每股基本收益为1.38美元。从资产负债表来看，Catalyst Pharmaceuticals, Inc.总负债1.27亿美元，其中短期债务402000.00美元，资产负债比为6.73，流动比率为5.16。机构评级：截至2025年3月3日，当前有8家机构对Catalyst Pharmaceuticals, Inc.目标价做出预测，其中目标均价为33.12美元，其中最低目标价为28.00美元，最高目标价为40.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303000232abe4acfe&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303000232abe4acfe&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CPRX"],"gpt_icon":0},{"id":"1127825978","title":"异动解读 | Catalyst Pharmaceutical Partners(CPRX)盘中大涨5.08%，盘面活跃受追捧","url":"https://stock-news.laohu8.com/highlight/detail?id=1127825978","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1127825978?lang=zh_cn&edition=full","pubTime":"2025-03-01 04:44","pubTimestamp":1740775472,"startTime":"0","endTime":"0","summary":"Catalyst Pharmaceutical Partners(CPRX)今日盘中大涨5.08%，引发市场关注。\n\n消息面上，CPRX最新的财报数据显示，公司实现营业收入4.92亿美元，净利润1.64亿美元，盈利能力强劲，每股收益1.38美元。此外，机构方面给予100%买入评级，看好公司长期发展前景。\n\n盘面上，CPRX今日盘中成交活跃，成交量达92.6048万股，换手率0.76%，振幅达4.85%。公司在生物技术行业内获追捧，整个板块也出现不错的上涨表现。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"异动解读 | Catalyst Pharmaceutical Partners(CPRX)盘中大涨5.08%，盘面活跃受追捧","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["CPRX"],"gpt_icon":0},{"id":"2516730955","title":"Catalyst Pharmaceuticals, Inc.盘中异动 急速拉升5.03%报22.75美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516730955","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516730955?lang=zh_cn&edition=full","pubTime":"2025-03-01 04:42","pubTimestamp":1740775320,"startTime":"0","endTime":"0","summary":"北京时间2025年03月01日04时42分，Catalyst Pharmaceuticals, Inc.股票出现异动，股价急速拉升5.03%。Catalyst Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.73%。其相关个股中，Cero Therapeutics Holdings Inc C/Wts 13/02/2029 、Camp4 Therapeutics Corporation、Enveric Biosciences, Inc.涨幅较大，Bioxcel Therapeutics, Inc.、Enveric Biosciences, Inc.、Virpax Pharmaceuticals, Inc.较为活跃，换手率分别为3281.85%、605.06%、401.08%，振幅较大的相关个股有Bioxcel Therapeutics, Inc.、Cardio Diagnostics Holdings Inc C/Wts  To Pur Com、Nrx Pharmaceuticals Inc C/Wts 24/05/2026 ，振幅分别为57.80%、49.90%、48.19%。Catalyst Pharmaceuticals, Inc.公司简介：Catalyst Pharmaceuticals Inc是一家生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025030104420096346500&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025030104420096346500&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","CPRX","IE00B19Z6F94.USD","IE0034390439.USD"],"gpt_icon":0},{"id":"1122460757","title":"异动解读 | Catalyst Pharmaceutical Partners公布亮眼业绩报告,股价盘中大涨10.84%","url":"https://stock-news.laohu8.com/highlight/detail?id=1122460757","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1122460757?lang=zh_cn&edition=full","pubTime":"2025-02-27 22:46","pubTimestamp":1740667600,"startTime":"0","endTime":"0","summary":"周四盘中交易期间,Catalyst Pharmaceutical Partners股价出现了大幅上涨,截至上午9:32,股价累计上涨10.84%,引发了市场的广泛关注。此前公司周三晚间公布的2024年第四季度业绩报告成为本轮上涨行情的主要推手。财报显示,Catalyst Pharmaceutical Partners当季每股收益0.70美元,远高于分析师平均预期的0.34美元。作为Catalyst Pharmaceutical Partners的核心产品,旗舰药品在过去一个季度保持了优异的销售业绩,为公司带来了强劲的营收增长。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["CPRX"],"gpt_icon":0},{"id":"2514385851","title":"Catalyst Pharmaceuticals, Inc.盘中异动 股价大涨8.45%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514385851","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514385851?lang=zh_cn&edition=full","pubTime":"2025-02-27 22:30","pubTimestamp":1740666645,"startTime":"0","endTime":"0","summary":"北京时间2025年02月27日22时30分，Catalyst Pharmaceuticals, Inc.股票出现波动，股价急速上涨8.45%。Catalyst Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.00%。其相关个股中，Quoin Pharmaceuticals Ltd、Pasithea Therapeutics Corp C/Wts 12/08/2026 、天演药业涨幅较大，Quoin Pharmaceuticals Ltd、Moleculin Biotech, Inc.、Aeon Biopharma, Inc.较为活跃，换手率分别为391.76%、89.32%、48.01%，振幅较大的相关个股有天演药业、内克塔治疗、Scorpius Holdings, Inc.，振幅分别为10.10%、7.64%、6.33%。Catalyst Pharmaceuticals, Inc.公司简介：Catalyst Pharmaceuticals Inc是一家生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227223045abdf6e2f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227223045abdf6e2f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ADAG","IE0034390439.USD","BK4139","IE00B19Z6F94.USD","CPRX"],"gpt_icon":0},{"id":"1164666029","title":"异动解读 | Catalyst Pharmaceutical Partners公布亮眼财报,股价盘前大涨8.6%","url":"https://stock-news.laohu8.com/highlight/detail?id=1164666029","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1164666029?lang=zh_cn&edition=full","pubTime":"2025-02-27 21:03","pubTimestamp":1740661408,"startTime":"0","endTime":"0","summary":"周四盘前交易中,Catalyst Pharmaceutical Partners股价大涨8.6%,引发了市场的广泛关注。数据显示,该股开盘参考价为15.35美元,较上一交易日收盘价上涨幅度达到8.6%。导致该股价大涨的主要原因是,该公司于周三晚间发布了2024年第四季度财报,营收和利润数据双双超出市场预期。Catalyst Pharmaceutical Partners的优异财报成绩主要源自公司旗舰产品在市场保持良好的销售势头,增强了投资者对该公司长期发展前景的信心,从而推动该公司在盘前交易中股价出现大幅上涨。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["CPRX"],"gpt_icon":0},{"id":"1187017244","title":"异动解读 | Catalyst Pharmaceutical Partners盘后大涨8.36%,财报数据超预期成主因","url":"https://stock-news.laohu8.com/highlight/detail?id=1187017244","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1187017244?lang=zh_cn&edition=full","pubTime":"2025-02-27 09:18","pubTimestamp":1740619129,"startTime":"0","endTime":"0","summary":"Catalyst Pharmaceutical Partners(纳斯达克代码:CPRX)周三夜盘大涨8.36%,引发了市场广泛关注。\n\n导致该股盘后大涨的主要原因是,公司新发布的2024年第四季度财报数据超出市场预期。财报显示,公司第四季度每股收益为0.70美元,高于分析师一致预期的0.34美元,同比增长32.08%;营收方面实现14.181亿美元,也超出预期的13.42亿美元,同比增长28.26%。\n\n优异的业绩表现体现了公司产品在市场的良好销售势头,增强了投资者对其长期发展前景的信心,从而推动公司盘后股价出现大幅上涨。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["CPRX"],"gpt_icon":0},{"id":"1164497473","title":"异动解读 | Catalyst Pharmaceutical Partners盘后大涨8.14% 财报数据超预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1164497473","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1164497473?lang=zh_cn&edition=full","pubTime":"2025-02-27 05:46","pubTimestamp":1740606396,"startTime":"0","endTime":"0","summary":"Catalyst Pharmaceutical Partners(CPRX)今日盘后大涨8.14%,引发市场高度关注。这主要归功于其刚公布的2024年第四季度财报数据实现大超预期。\n\n财报显示,公司本季度每股收益为0.70美元,高于分析师一致预期的0.34美元,同比增长32.08%。营收方面,公司本季度实现14.181亿美元,也高于分析师预期的13.42亿美元,同比增长28.26%。\n\n优异的业绩表现体现了公司产品在市场的良好销售态势,这进一步增强了投资者对公司的信心,带动了其盘后股价的大幅上涨。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["CPRX"],"gpt_icon":0},{"id":"1129283897","title":"药物催化剂公司2024年第四季度调整后每股收益$0.70 高于预期$0.34，销售额$1.4181亿 超过预期$1.342亿","url":"https://stock-news.laohu8.com/highlight/detail?id=1129283897","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1129283897?lang=zh_cn&edition=full","pubTime":"2025-02-27 05:32","pubTimestamp":1740605558,"startTime":"0","endTime":"0","summary":"药物催化剂公司报告季度每股收益$0.70，比分析师一致预期的$0.34高出105.88%。这比去年同期的每股收益$0.53增长了32.08%。公司报告季度销售额为$1.4181亿，超过分析师一致预期的$1.342亿，高出5.67%。以上内容来自Benzinga Earnings专栏，原文如下：Catalyst Pharmaceuticals  reported quarterly earnings of $0.70 per share which beat the analyst consensus estimate of $0.34 by 105.88 percent. This is a 32.08 percent increase over earnings of $0.53 per share from the same period last year.  The company reported quarterly sales of $141.81 million which beat the analyst consensus estimate of $134.20 mi","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"药物催化剂公司2024年第四季度调整后每股收益$0.70 高于预期$0.34，销售额$1.4181亿 超过预期$1.342亿","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CPRX"],"gpt_icon":0},{"id":"2502686500","title":"HC Wainwright & Co.：维持Catalyst Pharmaceuticals(CPRX.US)评级，由买入调整至买入评级, 目标价由30.00美元调整至35.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2502686500","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2502686500?lang=zh_cn&edition=full","pubTime":"2025-01-10 21:27","pubTimestamp":1736515664,"startTime":"0","endTime":"0","summary":"HC Wainwright & Co.：维持Catalyst Pharmaceuticals(CPRX.US)评级，由买入调整至买入评级, 目标价由30.00美元调整至35.00美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/01/10212747358713.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["CPRX"],"gpt_icon":0},{"id":"2483383028","title":"Catalyst Pharmaceuticals, Inc.2024财年第三财季实现净利润43.88百万美元，同比增加242.65%","url":"https://stock-news.laohu8.com/highlight/detail?id=2483383028","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483383028?lang=zh_cn&edition=full","pubTime":"2024-11-15 00:02","pubTimestamp":1731600145,"startTime":"0","endTime":"0","summary":"11月15日，Catalyst Pharmaceuticals, Inc.公布财报，公告显示公司2024财年第三财季净利润为43.88百万美元，同比增加242.65%；其中营业收入为1.29亿美元，同比增加25.24%，每股基本收益为0.37美元。从资产负债表来看，Catalyst Pharmaceuticals, Inc.总负债1.11亿美元，其中短期债务393000.00美元，资产负债比为6.96，流动比率为5.14。机构评级：截至2024年11月15日，当前有7家机构对Catalyst Pharmaceuticals, Inc.目标价做出预测，其中目标均价为31.86美元，其中最低目标价为28.00美元，最高目标价为38.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241115000303a23801c7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241115000303a23801c7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CPRX"],"gpt_icon":0},{"id":"1129925010","title":"异动解读 | 催化剂公司财报利好推动股价大涨","url":"https://stock-news.laohu8.com/highlight/detail?id=1129925010","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1129925010?lang=zh_cn&edition=full","pubTime":"2024-11-08 10:46","pubTimestamp":1731033995,"startTime":"0","endTime":"0","summary":"专注罕见病药物研发的催化剂制药公司股价今日盘前大涨6.78%,最高触及18.4美元,引发市场关注。公司上周公布的最新季度业绩显着超预期成为主要推手。财报数据显示,催化剂公司第三季度营收同比大增25.3%至1.287亿美元,高于分析师平均预期。同时归属普通股东的净利润达4388万美元,去年同期为亏损。受业绩超预期利好因素影响,华尔街分析师纷纷上调对该股的评级和目标价。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["CPRX"],"gpt_icon":0},{"id":"1173258752","title":"异动解读 | 催化剂公司三季度业绩超预期 盘前大涨6.78%","url":"https://stock-news.laohu8.com/highlight/detail?id=1173258752","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1173258752?lang=zh_cn&edition=full","pubTime":"2024-11-07 21:03","pubTimestamp":1730984611,"startTime":"0","endTime":"0","summary":"罕见病药物公司催化剂制药公司今日盘前大涨6.78%,股价最高触及18.4美元,引发市场关注。分析人士认为,公司最新季度业绩超预期是主要原因。该公司上周公布的第三季度财报显示,营收同比大增25.3%至1.287亿美元,超出分析师预期。归属普通股东净利润达4388万美元,去年同期为亏损。凭借财报利好因素,分析师普遍看好催化剂公司长期前景。华尔街分析师给予该股一致\"买入\"评级,平均12个月目标价为30美元,预计仍有16%的上涨空间。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["CPRX"],"gpt_icon":0},{"id":"1108663842","title":"异动解读 | Catalyst Pharmaceuticals去季度业绩大增股价应声飙升","url":"https://stock-news.laohu8.com/highlight/detail?id=1108663842","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1108663842?lang=zh_cn&edition=full","pubTime":"2024-11-07 13:17","pubTimestamp":1730956627,"startTime":"0","endTime":"0","summary":"专注于罕见肌肉病研发的Catalyst Pharmaceuticals公司股价周二收盘大涨9.2%。Catalyst最新财报显示,公司第三季度实现营收1.287亿美元,同比大增25.3%;归属普通股股东的净利润4388万美元,去年同期为亏损;每股收益0.35美元,高于分析师平均预期的0.30美元。Catalyst表示,未来将通过开发创新产品不断扩大在神经肌肉疾病领域的覆盖范围。由于财报超预期,华尔街分析师普遍给予Catalyst股票\"买入\"评级,最新一致目标价为30美元,较当前水平有16%的上涨空间。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["CPRX"],"gpt_icon":0},{"id":"2481834599","title":"Catalyst Pharmaceuticals, Inc.盘中异动 早盘股价大涨5.28%","url":"https://stock-news.laohu8.com/highlight/detail?id=2481834599","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481834599?lang=zh_cn&edition=full","pubTime":"2024-11-06 22:31","pubTimestamp":1730903488,"startTime":"0","endTime":"0","summary":"北京时间2024年11月06日22时31分，Catalyst Pharmaceuticals, Inc.股票出现波动，股价快速拉升5.28%。Catalyst Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.91%。其相关个股中，Sonnet Biotherapeutics Holdings, Inc.、Lixte Biotechnology Holdings  Inc C/Wts 30/11/2025 、Sab Biotherapeutics Inc C/Wts 22/10/2026 涨幅较大，Sonnet Biotherapeutics Holdings, Inc.、Elevai Labs, Inc.、Zyversa Therapeutics, Inc.较为活跃，换手率分别为1011.50%、97.66%、48.12%，振幅较大的相关个股有Theratechnologies Inc.、Ovid Therapeutics Inc.、Elevai Labs, Inc.，振幅分别为9.37%、8.80%、7.48%。Catalyst Pharmaceuticals, Inc.公司简介：Catalyst Pharmaceuticals Inc是一家生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024110622312898e40d72&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024110622312898e40d72&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4183","ELAB","CPRX","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.catalystpharma.com","stockEarnings":[{"period":"1week","weight":0.044},{"period":"1month","weight":0.0431},{"period":"3month","weight":0.2048},{"period":"6month","weight":0.0601},{"period":"1year","weight":0.131},{"period":"ytd","weight":0.1586}],"compareEarnings":[{"period":"1week","weight":-0.0042},{"period":"1month","weight":0.0131},{"period":"3month","weight":0.0314},{"period":"6month","weight":0.1394},{"period":"1year","weight":0.1266},{"period":"ytd","weight":0.1615}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Catalyst Pharmaceuticals, Inc.于2006年7月在特拉华州注册成立。该公司是一家商业阶段、以患者为中心的生物制药公司，专注于为患有罕见和难以治疗的疾病的患者提供新的高质量药物的许可、开发和商业化。该公司利用协调一致的勤奋努力，寻找能够改善那些患有罕见或难以治疗的疾病的人的生活的疗法。","yearOnYearQuotes":[{"month":1,"riseRate":0.578947,"avgChangeRate":0.055293},{"month":2,"riseRate":0.684211,"avgChangeRate":-0.010782},{"month":3,"riseRate":0.684211,"avgChangeRate":0.101942},{"month":4,"riseRate":0.421053,"avgChangeRate":0.03478},{"month":5,"riseRate":0.578947,"avgChangeRate":-0.029537},{"month":6,"riseRate":0.526316,"avgChangeRate":0.038372},{"month":7,"riseRate":0.578947,"avgChangeRate":0.111528},{"month":8,"riseRate":0.631579,"avgChangeRate":0.2208},{"month":9,"riseRate":0.368421,"avgChangeRate":-0.027783},{"month":10,"riseRate":0.473684,"avgChangeRate":-0.048724},{"month":11,"riseRate":0.578947,"avgChangeRate":0.015249},{"month":12,"riseRate":0.35,"avgChangeRate":-0.028193}],"exchange":"NASDAQ","name":"Catalyst Pharmaceutical Partners","nameEN":"Catalyst Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Catalyst Pharmaceutical Partners(CPRX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Catalyst Pharmaceutical Partners(CPRX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Catalyst Pharmaceutical Partners,CPRX,Catalyst Pharmaceutical Partners股票,Catalyst Pharmaceutical Partners股票老虎,Catalyst Pharmaceutical Partners股票老虎国际,Catalyst Pharmaceutical Partners行情,Catalyst Pharmaceutical Partners股票行情,Catalyst Pharmaceutical Partners股价,Catalyst Pharmaceutical Partners股市,Catalyst Pharmaceutical Partners股票价格,Catalyst Pharmaceutical Partners股票交易,Catalyst Pharmaceutical Partners股票购买,Catalyst Pharmaceutical Partners股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Catalyst Pharmaceutical Partners(CPRX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Catalyst Pharmaceutical Partners(CPRX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}